<?xml version="1.0" encoding="UTF-8" ?>
<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</dc:title>
<dc:creator>Aterido Ballonga, Adrià, 1990-</dc:creator>
<dc:creator>Cañete Crespillo, Juan de Dios</dc:creator>
<dc:creator>Tornero, Jesús</dc:creator>
<dc:creator>Blanco, Francisco</dc:creator>
<dc:creator>Fernández-Gutiérrez, Benjamín</dc:creator>
<dc:creator>Pérez-García, Carolina</dc:creator>
<dc:creator>Alperiz, Mercedes</dc:creator>
<dc:creator>Olivé, Alex</dc:creator>
<dc:creator>Corominas, Héctor</dc:creator>
<dc:creator>Martínez-Taboada, Víctor</dc:creator>
<dc:creator>González-Alvaro, Isidoro</dc:creator>
<dc:creator>Fernández-Nebro, Antonio</dc:creator>
<dc:creator>Erra, Alba</dc:creator>
<dc:creator>López Lasanta, María</dc:creator>
<dc:creator>López Corbeto, Mireia</dc:creator>
<dc:creator>Palau, Núria</dc:creator>
<dc:creator>Marsal, Sara</dc:creator>
<dc:creator>Julià, Antonio</dc:creator>
<dc:subject>Anti-TNF therapy</dc:subject>
<dc:subject>Genomics</dc:subject>
<dc:subject>Multi-omics association analysis</dc:subject>
<dc:subject>Rheumatoid arthritis</dc:subject>
<dc:subject>Transcriptomics</dc:subject>
<dc:description>Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</dc:description>
<dc:date>2019</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:identifier>Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</dc:identifier>
<dc:identifier>1664-3224</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/43304</dc:identifier>
<dc:identifier>http://dx.doi.org/10.3389/fimmu.2019.01459</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Frontiers in Immunology. 2019 Jul 2;10:1459</dc:relation>
<dc:rights>Copyright © 2019 Aterido, Cañete, Tornero, Blanco, Fernández-Gutierrez, Pérez, Alperi-López, Olivè, Corominas, Martínez-Taboada, González, Fernández-Nebro, Erra, López-Lasanta, López Corbeto, Palau, Marsal and Julià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</dc:rights>
<dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:format>application/pdf</dc:format>
<dc:publisher>Frontiers</dc:publisher>
</oai_dc:dc>
<?xml version="1.0" encoding="UTF-8" ?>
<d:DIDL schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
<d:DIDLInfo>
<dcterms:created schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2020-01-17T08:00:51Z</dcterms:created>
</d:DIDLInfo>
<d:Item id="hdl_10230_43304">
<d:Descriptor>
<d:Statement mimeType="application/xml; charset=utf-8">
<dii:Identifier schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:10230/43304</dii:Identifier>
</d:Statement>
</d:Descriptor>
<d:Descriptor>
<d:Statement mimeType="application/xml; charset=utf-8">
<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</dc:title>
<dc:creator>Aterido Ballonga, Adrià, 1990-</dc:creator>
<dc:creator>Cañete Crespillo, Juan de Dios</dc:creator>
<dc:creator>Tornero, Jesús</dc:creator>
<dc:creator>Blanco, Francisco</dc:creator>
<dc:creator>Fernández-Gutiérrez, Benjamín</dc:creator>
<dc:creator>Pérez-García, Carolina</dc:creator>
<dc:creator>Alperiz, Mercedes</dc:creator>
<dc:creator>Olivé, Alex</dc:creator>
<dc:creator>Corominas, Héctor</dc:creator>
<dc:creator>Martínez-Taboada, Víctor</dc:creator>
<dc:creator>González-Alvaro, Isidoro</dc:creator>
<dc:creator>Fernández-Nebro, Antonio</dc:creator>
<dc:creator>Erra, Alba</dc:creator>
<dc:creator>López Lasanta, María</dc:creator>
<dc:creator>López Corbeto, Mireia</dc:creator>
<dc:creator>Palau, Núria</dc:creator>
<dc:creator>Marsal, Sara</dc:creator>
<dc:creator>Julià, Antonio</dc:creator>
<dc:description>Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</dc:description>
<dc:date>2020-01-17T08:00:51Z</dc:date>
<dc:date>2020-01-17T08:00:51Z</dc:date>
<dc:date>2019</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</dc:identifier>
<dc:identifier>1664-3224</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/43304</dc:identifier>
<dc:identifier>http://dx.doi.org/10.3389/fimmu.2019.01459</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Frontiers in Immunology. 2019 Jul 2;10:1459</dc:relation>
<dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>Copyright © 2019 Aterido, Cañete, Tornero, Blanco, Fernández-Gutierrez, Pérez, Alperi-López, Olivè, Corominas, Martínez-Taboada, González, Fernández-Nebro, Erra, López-Lasanta, López Corbeto, Palau, Marsal and Julià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</dc:rights>
<dc:publisher>Frontiers</dc:publisher>
</oai_dc:dc>
</d:Statement>
</d:Descriptor>
<d:Component id="10230_43304_1">
</d:Component>
</d:Item>
</d:DIDL>
<?xml version="1.0" encoding="UTF-8" ?>
<dim:dim schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
<dim:field element="contributor" mdschema="dc" qualifier="author">Aterido Ballonga, Adrià, 1990-</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Cañete Crespillo, Juan de Dios</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Tornero, Jesús</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Blanco, Francisco</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Fernández-Gutiérrez, Benjamín</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Pérez-García, Carolina</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Alperiz, Mercedes</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Olivé, Alex</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Corominas, Héctor</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Martínez-Taboada, Víctor</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">González-Alvaro, Isidoro</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Fernández-Nebro, Antonio</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Erra, Alba</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">López Lasanta, María</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">López Corbeto, Mireia</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Palau, Núria</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Marsal, Sara</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Julià, Antonio</dim:field>
<dim:field element="date" mdschema="dc" qualifier="accessioned">2020-01-17T08:00:51Z</dim:field>
<dim:field element="date" mdschema="dc" qualifier="available">2020-01-17T08:00:51Z</dim:field>
<dim:field element="date" mdschema="dc" qualifier="issued">2019</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="citation">Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="issn">1664-3224</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="uri">http://hdl.handle.net/10230/43304</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="doi">http://dx.doi.org/10.3389/fimmu.2019.01459</dim:field>
<dim:field element="description" mdschema="dc" qualifier="abstract">Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</dim:field>
<dim:field element="description" lang="en" mdschema="dc" qualifier="provenance">Made available in DSpace on 2020-01-17T08:00:51Z (GMT). No. of bitstreams: 1 aterido-fii-comb.pdf: 999332 bytes, checksum: f6b7b910b3c9dbaf04fba9d71875bd76 (MD5) Previous issue date: 2019</dim:field>
<dim:field element="format" mdschema="dc" qualifier="mimetype">application/pdf</dim:field>
<dim:field element="language" mdschema="dc" qualifier="iso">eng</dim:field>
<dim:field element="publisher" mdschema="dc">Frontiers</dim:field>
<dim:field element="relation" mdschema="dc" qualifier="ispartof">Frontiers in Immunology. 2019 Jul 2;10:1459</dim:field>
<dim:field element="rights" mdschema="dc">Copyright © 2019 Aterido, Cañete, Tornero, Blanco, Fernández-Gutierrez, Pérez, Alperi-López, Olivè, Corominas, Martínez-Taboada, González, Fernández-Nebro, Erra, López-Lasanta, López Corbeto, Palau, Marsal and Julià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</dim:field>
<dim:field element="rights" mdschema="dc" qualifier="uri">https://creativecommons.org/licenses/by/4.0/</dim:field>
<dim:field element="rights" mdschema="dc" qualifier="accessRights">info:eu-repo/semantics/openAccess</dim:field>
<dim:field element="title" mdschema="dc">A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</dim:field>
<dim:field element="type" mdschema="dc">info:eu-repo/semantics/article</dim:field>
<dim:field element="type" mdschema="dc" qualifier="version">info:eu-repo/semantics/publishedVersion</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Anti-TNF therapy</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Genomics</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Multi-omics association analysis</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Rheumatoid arthritis</dim:field>
<dim:field element="subject" mdschema="dc" qualifier="keyword">Transcriptomics</dim:field>
</dim:dim>
<?xml version="1.0" encoding="UTF-8" ?>
<thesis schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">
<title>A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</title>
<creator>Aterido Ballonga, Adrià, 1990-</creator>
<creator>Cañete Crespillo, Juan de Dios</creator>
<creator>Tornero, Jesús</creator>
<creator>Blanco, Francisco</creator>
<creator>Fernández-Gutiérrez, Benjamín</creator>
<creator>Pérez-García, Carolina</creator>
<creator>Alperiz, Mercedes</creator>
<creator>Olivé, Alex</creator>
<creator>Corominas, Héctor</creator>
<creator>Martínez-Taboada, Víctor</creator>
<creator>González-Alvaro, Isidoro</creator>
<creator>Fernández-Nebro, Antonio</creator>
<creator>Erra, Alba</creator>
<creator>López Lasanta, María</creator>
<creator>López Corbeto, Mireia</creator>
<creator>Palau, Núria</creator>
<creator>Marsal, Sara</creator>
<creator>Julià, Antonio</creator>
<description>Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</description>
<date>2020-01-17</date>
<date>2020-01-17</date>
<date>2019</date>
<type>info:eu-repo/semantics/article</type>
<identifier>Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</identifier>
<identifier>1664-3224</identifier>
<identifier>http://hdl.handle.net/10230/43304</identifier>
<identifier>http://dx.doi.org/10.3389/fimmu.2019.01459</identifier>
<language>eng</language>
<relation>Frontiers in Immunology. 2019 Jul 2;10:1459</relation>
<rights>https://creativecommons.org/licenses/by/4.0/</rights>
<rights>info:eu-repo/semantics/openAccess</rights>
<rights>Copyright © 2019 Aterido, Cañete, Tornero, Blanco, Fernández-Gutierrez, Pérez, Alperi-López, Olivè, Corominas, Martínez-Taboada, González, Fernández-Nebro, Erra, López-Lasanta, López Corbeto, Palau, Marsal and Julià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</rights>
<publisher>Frontiers</publisher>
</thesis>
<?xml version="1.0" encoding="UTF-8" ?>
<record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
<leader>00925njm 22002777a 4500</leader>
<datafield ind1=" " ind2=" " tag="042">
<subfield code="a">dc</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Aterido Ballonga, Adrià, 1990-</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Cañete Crespillo, Juan de Dios</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Tornero, Jesús</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Blanco, Francisco</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Fernández-Gutiérrez, Benjamín</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Pérez-García, Carolina</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Alperiz, Mercedes</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Olivé, Alex</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Corominas, Héctor</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Martínez-Taboada, Víctor</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">González-Alvaro, Isidoro</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Fernández-Nebro, Antonio</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Erra, Alba</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">López Lasanta, María</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">López Corbeto, Mireia</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Palau, Núria</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Marsal, Sara</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Julià, Antonio</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="260">
<subfield code="c">2019</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="520">
<subfield code="a">Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">1664-3224</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">http://hdl.handle.net/10230/43304</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">http://dx.doi.org/10.3389/fimmu.2019.01459</subfield>
</datafield>
<datafield ind1="0" ind2="0" tag="245">
<subfield code="a">A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</subfield>
</datafield>
</record>
<?xml version="1.0" encoding="UTF-8" ?>
<mets ID=" DSpace_ITEM_10230-43304" OBJID=" hdl:10230/43304" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd">
<metsHdr CREATEDATE="2022-11-15T20:51:35Z">
<agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
<name>Repositori digital de la UPF</name>
</agent>
</metsHdr>
<dmdSec ID="DMD_10230_43304">
<mdWrap MDTYPE="MODS">
<xmlData schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Aterido Ballonga, Adrià, 1990-</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Cañete Crespillo, Juan de Dios</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Tornero, Jesús</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Blanco, Francisco</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Fernández-Gutiérrez, Benjamín</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Pérez-García, Carolina</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Alperiz, Mercedes</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Olivé, Alex</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Corominas, Héctor</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Martínez-Taboada, Víctor</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>González-Alvaro, Isidoro</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Fernández-Nebro, Antonio</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Erra, Alba</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>López Lasanta, María</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>López Corbeto, Mireia</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Palau, Núria</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Marsal, Sara</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Julià, Antonio</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2020-01-17T08:00:51Z</mods:dateAccessioned>
</mods:extension>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2020-01-17T08:00:51Z</mods:dateAvailable>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2019</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</mods:identifier>
<mods:identifier type="issn">1664-3224</mods:identifier>
<mods:identifier type="uri">http://hdl.handle.net/10230/43304</mods:identifier>
<mods:identifier type="doi">http://dx.doi.org/10.3389/fimmu.2019.01459</mods:identifier>
<mods:abstract>Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</mods:abstract>
<mods:language>
<mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">Copyright © 2019 Aterido, Cañete, Tornero, Blanco, Fernández-Gutierrez, Pérez, Alperi-López, Olivè, Corominas, Martínez-Taboada, González, Fernández-Nebro, Erra, López-Lasanta, López Corbeto, Palau, Marsal and Julià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</mods:accessCondition>
<mods:titleInfo>
<mods:title>A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods>
</xmlData>
</mdWrap>
</dmdSec>
<amdSec ID="FO_10230_43304_1">
<techMD ID="TECH_O_10230_43304_1">
<mdWrap MDTYPE="PREMIS">
<xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
<premis:premis>
<premis:object>
<premis:objectIdentifier>
<premis:objectIdentifierType>URL</premis:objectIdentifierType>
<premis:objectIdentifierValue>http://repositori.upf.edu/bitstream/10230/43304/1/aterido-fii-comb.pdf</premis:objectIdentifierValue>
</premis:objectIdentifier>
<premis:objectCategory>File</premis:objectCategory>
<premis:objectCharacteristics>
<premis:fixity>
<premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
<premis:messageDigest>f6b7b910b3c9dbaf04fba9d71875bd76</premis:messageDigest>
</premis:fixity>
<premis:size>999332</premis:size>
<premis:format>
<premis:formatDesignation>
<premis:formatName>application/pdf</premis:formatName>
</premis:formatDesignation>
</premis:format>
</premis:objectCharacteristics>
<premis:originalName>aterido-fii-comb.pdf</premis:originalName>
</premis:object>
</premis:premis>
</xmlData>
</mdWrap>
</techMD>
</amdSec>
<amdSec ID="FT_10230_43304_2">
<techMD ID="TECH_T_10230_43304_2">
<mdWrap MDTYPE="PREMIS">
<xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
<premis:premis>
<premis:object>
<premis:objectIdentifier>
<premis:objectIdentifierType>URL</premis:objectIdentifierType>
<premis:objectIdentifierValue>http://repositori.upf.edu/bitstream/10230/43304/2/aterido-fii-comb.pdf.txt</premis:objectIdentifierValue>
</premis:objectIdentifier>
<premis:objectCategory>File</premis:objectCategory>
<premis:objectCharacteristics>
<premis:fixity>
<premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
<premis:messageDigest>aa01610babf740550a64154fbb3e1060</premis:messageDigest>
</premis:fixity>
<premis:size>75213</premis:size>
<premis:format>
<premis:formatDesignation>
<premis:formatName>text/plain</premis:formatName>
</premis:formatDesignation>
</premis:format>
</premis:objectCharacteristics>
<premis:originalName>aterido-fii-comb.pdf.txt</premis:originalName>
</premis:object>
</premis:premis>
</xmlData>
</mdWrap>
</techMD>
</amdSec>
<fileSec>
<fileGrp USE="ORIGINAL">
<file ADMID="FO_10230_43304_1" CHECKSUM="f6b7b910b3c9dbaf04fba9d71875bd76" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10230_43304_1" ID="BITSTREAM_ORIGINAL_10230_43304_1" MIMETYPE="application/pdf" SEQ="1" SIZE="999332">
</file>
</fileGrp>
<fileGrp USE="TEXT">
<file ADMID="FT_10230_43304_2" CHECKSUM="aa01610babf740550a64154fbb3e1060" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10230_43304_2" ID="BITSTREAM_TEXT_10230_43304_2" MIMETYPE="text/plain" SEQ="2" SIZE="75213">
</file>
</fileGrp>
</fileSec>
<structMap LABEL="DSpace Object" TYPE="LOGICAL">
<div ADMID="DMD_10230_43304" TYPE="DSpace Object Contents">
<div TYPE="DSpace BITSTREAM">
</div>
</div>
</structMap>
</mets>
<?xml version="1.0" encoding="UTF-8" ?>
<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Aterido Ballonga, Adrià, 1990-</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Cañete Crespillo, Juan de Dios</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Tornero, Jesús</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Blanco, Francisco</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Fernández-Gutiérrez, Benjamín</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Pérez-García, Carolina</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Alperiz, Mercedes</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Olivé, Alex</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Corominas, Héctor</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Martínez-Taboada, Víctor</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>González-Alvaro, Isidoro</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Fernández-Nebro, Antonio</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Erra, Alba</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>López Lasanta, María</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>López Corbeto, Mireia</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Palau, Núria</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Marsal, Sara</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Julià, Antonio</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2020-01-17T08:00:51Z</mods:dateAvailable>
</mods:extension>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2020-01-17T08:00:51Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2019</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</mods:identifier>
<mods:identifier type="issn">1664-3224</mods:identifier>
<mods:identifier type="uri">http://hdl.handle.net/10230/43304</mods:identifier>
<mods:identifier type="doi">http://dx.doi.org/10.3389/fimmu.2019.01459</mods:identifier>
<mods:abstract>Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">https://creativecommons.org/licenses/by/4.0/</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">Copyright © 2019 Aterido, Cañete, Tornero, Blanco, Fernández-Gutierrez, Pérez, Alperi-López, Olivè, Corominas, Martínez-Taboada, González, Fernández-Nebro, Erra, López-Lasanta, López Corbeto, Palau, Marsal and Julià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</mods:accessCondition>
<mods:titleInfo>
<mods:title>A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods>
<?xml version="1.0" encoding="UTF-8" ?>
<atom:entry schemaLocation="http://www.w3.org/2005/Atom http://www.kbcafe.com/rss/atom.xsd.xml">
<atom:id>http://oai-repositori.upf.edu/oai/metadata/handle/10230/43304/ore.xml</atom:id>
<atom:published>2020-01-17T08:00:51Z</atom:published>
<atom:updated>2020-01-17T08:00:51Z</atom:updated>
<atom:source>
<atom:generator>Repositori digital de la UPF</atom:generator>
</atom:source>
<atom:title>A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</atom:title>
<atom:author>
<atom:name>Aterido Ballonga, Adrià, 1990-</atom:name>
</atom:author>
<atom:author>
<atom:name>Cañete Crespillo, Juan de Dios</atom:name>
</atom:author>
<atom:author>
<atom:name>Tornero, Jesús</atom:name>
</atom:author>
<atom:author>
<atom:name>Blanco, Francisco</atom:name>
</atom:author>
<atom:author>
<atom:name>Fernández-Gutiérrez, Benjamín</atom:name>
</atom:author>
<atom:author>
<atom:name>Pérez-García, Carolina</atom:name>
</atom:author>
<atom:author>
<atom:name>Alperiz, Mercedes</atom:name>
</atom:author>
<atom:author>
<atom:name>Olivé, Alex</atom:name>
</atom:author>
<atom:author>
<atom:name>Corominas, Héctor</atom:name>
</atom:author>
<atom:author>
<atom:name>Martínez-Taboada, Víctor</atom:name>
</atom:author>
<atom:author>
<atom:name>González-Alvaro, Isidoro</atom:name>
</atom:author>
<atom:author>
<atom:name>Fernández-Nebro, Antonio</atom:name>
</atom:author>
<atom:author>
<atom:name>Erra, Alba</atom:name>
</atom:author>
<atom:author>
<atom:name>López Lasanta, María</atom:name>
</atom:author>
<atom:author>
<atom:name>López Corbeto, Mireia</atom:name>
</atom:author>
<atom:author>
<atom:name>Palau, Núria</atom:name>
</atom:author>
<atom:author>
<atom:name>Marsal, Sara</atom:name>
</atom:author>
<atom:author>
<atom:name>Julià, Antonio</atom:name>
</atom:author>
<oreatom:triples>
<rdf:Description about="http://oai-repositori.upf.edu/oai/metadata/handle/10230/43304/ore.xml#atom">
<dcterms:modified>2020-01-17T08:00:51Z</dcterms:modified>
</rdf:Description>
<rdf:Description about="http://repositori.upf.edu/bitstream/10230/43304/3/aterido-fii-comb.pdf.jpg">
<dcterms:description>THUMBNAIL</dcterms:description>
</rdf:Description>
<rdf:Description about="http://repositori.upf.edu/bitstream/10230/43304/2/aterido-fii-comb.pdf.txt">
<dcterms:description>TEXT</dcterms:description>
</rdf:Description>
<rdf:Description about="http://repositori.upf.edu/bitstream/10230/43304/1/aterido-fii-comb.pdf">
<dcterms:description>ORIGINAL</dcterms:description>
</rdf:Description>
</oreatom:triples>
</atom:entry>
<?xml version="1.0" encoding="UTF-8" ?>
<qdc:qualifieddc schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
<dc:title>A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</dc:title>
<dc:creator>Aterido Ballonga, Adrià, 1990-</dc:creator>
<dc:creator>Cañete Crespillo, Juan de Dios</dc:creator>
<dc:creator>Tornero, Jesús</dc:creator>
<dc:creator>Blanco, Francisco</dc:creator>
<dc:creator>Fernández-Gutiérrez, Benjamín</dc:creator>
<dc:creator>Pérez-García, Carolina</dc:creator>
<dc:creator>Alperiz, Mercedes</dc:creator>
<dc:creator>Olivé, Alex</dc:creator>
<dc:creator>Corominas, Héctor</dc:creator>
<dc:creator>Martínez-Taboada, Víctor</dc:creator>
<dc:creator>González-Alvaro, Isidoro</dc:creator>
<dc:creator>Fernández-Nebro, Antonio</dc:creator>
<dc:creator>Erra, Alba</dc:creator>
<dc:creator>López Lasanta, María</dc:creator>
<dc:creator>López Corbeto, Mireia</dc:creator>
<dc:creator>Palau, Núria</dc:creator>
<dc:creator>Marsal, Sara</dc:creator>
<dc:creator>Julià, Antonio</dc:creator>
<dcterms:abstract>Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</dcterms:abstract>
<dc:date>2019</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</dc:identifier>
<dc:identifier>1664-3224</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/43304</dc:identifier>
<dc:identifier>http://dx.doi.org/10.3389/fimmu.2019.01459</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Frontiers in Immunology. 2019 Jul 2;10:1459</dc:relation>
<dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>Copyright © 2019 Aterido, Cañete, Tornero, Blanco, Fernández-Gutierrez, Pérez, Alperi-López, Olivè, Corominas, Martínez-Taboada, González, Fernández-Nebro, Erra, López-Lasanta, López Corbeto, Palau, Marsal and Julià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</dc:rights>
<dc:publisher>Frontiers</dc:publisher>
</qdc:qualifieddc>
<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
<ow:Publication about="oai:repositori.upf.edu:10230/43304">
<dc:title>A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</dc:title>
<dc:creator>Aterido Ballonga, Adrià, 1990-</dc:creator>
<dc:creator>Cañete Crespillo, Juan de Dios</dc:creator>
<dc:creator>Tornero, Jesús</dc:creator>
<dc:creator>Blanco, Francisco</dc:creator>
<dc:creator>Fernández-Gutiérrez, Benjamín</dc:creator>
<dc:creator>Pérez-García, Carolina</dc:creator>
<dc:creator>Alperiz, Mercedes</dc:creator>
<dc:creator>Olivé, Alex</dc:creator>
<dc:creator>Corominas, Héctor</dc:creator>
<dc:creator>Martínez-Taboada, Víctor</dc:creator>
<dc:creator>González-Alvaro, Isidoro</dc:creator>
<dc:creator>Fernández-Nebro, Antonio</dc:creator>
<dc:creator>Erra, Alba</dc:creator>
<dc:creator>López Lasanta, María</dc:creator>
<dc:creator>López Corbeto, Mireia</dc:creator>
<dc:creator>Palau, Núria</dc:creator>
<dc:creator>Marsal, Sara</dc:creator>
<dc:creator>Julià, Antonio</dc:creator>
<dc:description>Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</dc:description>
<dc:date>2019</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</dc:identifier>
<dc:identifier>1664-3224</dc:identifier>
<dc:identifier>http://hdl.handle.net/10230/43304</dc:identifier>
<dc:identifier>http://dx.doi.org/10.3389/fimmu.2019.01459</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Frontiers in Immunology. 2019 Jul 2;10:1459</dc:relation>
<dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>Copyright © 2019 Aterido, Cañete, Tornero, Blanco, Fernández-Gutierrez, Pérez, Alperi-López, Olivè, Corominas, Martínez-Taboada, González, Fernández-Nebro, Erra, López-Lasanta, López Corbeto, Palau, Marsal and Julià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</dc:rights>
<dc:publisher>Frontiers</dc:publisher>
</ow:Publication>
</rdf:RDF>
<?xml version="1.0" encoding="UTF-8" ?>
<metadata schemaLocation="http://www.lyncode.com/xoai http://www.lyncode.com/xsd/xoai.xsd">
<element name="dc">
<element name="contributor">
<element name="author">
<element name="none">
<field name="value">Aterido Ballonga, Adrià, 1990-</field>
<field name="value">Cañete Crespillo, Juan de Dios</field>
<field name="value">Tornero, Jesús</field>
<field name="value">Blanco, Francisco</field>
<field name="value">Fernández-Gutiérrez, Benjamín</field>
<field name="value">Pérez-García, Carolina</field>
<field name="value">Alperiz, Mercedes</field>
<field name="value">Olivé, Alex</field>
<field name="value">Corominas, Héctor</field>
<field name="value">Martínez-Taboada, Víctor</field>
<field name="value">González-Alvaro, Isidoro</field>
<field name="value">Fernández-Nebro, Antonio</field>
<field name="value">Erra, Alba</field>
<field name="value">López Lasanta, María</field>
<field name="value">López Corbeto, Mireia</field>
<field name="value">Palau, Núria</field>
<field name="value">Marsal, Sara</field>
<field name="value">Julià, Antonio</field>
</element>
</element>
</element>
<element name="date">
<element name="accessioned">
<element name="none">
<field name="value">2020-01-17T08:00:51Z</field>
</element>
</element>
<element name="available">
<element name="none">
<field name="value">2020-01-17T08:00:51Z</field>
</element>
</element>
<element name="issued">
<element name="none">
<field name="value">2019</field>
</element>
</element>
</element>
<element name="identifier">
<element name="citation">
<element name="none">
<field name="value">Aterido A, Cañete JD, Tornero J, Blanco F, Fernández-Gutierrez B, Pérez C et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2019 Jul 2;10:1459. DOI: 10.3389/fimmu.2019.01459</field>
</element>
</element>
<element name="issn">
<element name="none">
<field name="value">1664-3224</field>
</element>
</element>
<element name="uri">
<element name="none">
<field name="value">http://hdl.handle.net/10230/43304</field>
</element>
</element>
<element name="doi">
<element name="none">
<field name="value">http://dx.doi.org/10.3389/fimmu.2019.01459</field>
</element>
</element>
</element>
<element name="description">
<element name="abstract">
<element name="none">
<field name="value">Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.</field>
</element>
</element>
<element name="provenance">
<element name="en">
<field name="value">Made available in DSpace on 2020-01-17T08:00:51Z (GMT). No. of bitstreams: 1 aterido-fii-comb.pdf: 999332 bytes, checksum: f6b7b910b3c9dbaf04fba9d71875bd76 (MD5) Previous issue date: 2019</field>
</element>
</element>
</element>
<element name="format">
<element name="mimetype">
<element name="none">
<field name="value">application/pdf</field>
</element>
</element>
</element>
<element name="language">
<element name="iso">
<element name="none">
<field name="value">eng</field>
</element>
</element>
</element>
<element name="publisher">
<element name="none">
<field name="value">Frontiers</field>
</element>
</element>
<element name="relation">
<element name="ispartof">
<element name="none">
<field name="value">Frontiers in Immunology. 2019 Jul 2;10:1459</field>
</element>
</element>
</element>
<element name="rights">
<element name="none">
<field name="value">Copyright © 2019 Aterido, Cañete, Tornero, Blanco, Fernández-Gutierrez, Pérez, Alperi-López, Olivè, Corominas, Martínez-Taboada, González, Fernández-Nebro, Erra, López-Lasanta, López Corbeto, Palau, Marsal and Julià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</field>
</element>
<element name="uri">
<element name="none">
<field name="value">https://creativecommons.org/licenses/by/4.0/</field>
</element>
</element>
<element name="accessRights">
<element name="none">
<field name="value">info:eu-repo/semantics/openAccess</field>
</element>
</element>
</element>
<element name="title">
<element name="none">
<field name="value">A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis</field>
</element>
</element>
<element name="type">
<element name="none">
<field name="value">info:eu-repo/semantics/article</field>
</element>
<element name="version">
<element name="none">
<field name="value">info:eu-repo/semantics/publishedVersion</field>
</element>
</element>
</element>
<element name="subject">
<element name="keyword">
<element name="none">
<field name="value">Anti-TNF therapy</field>
<field name="value">Genomics</field>
<field name="value">Multi-omics association analysis</field>
<field name="value">Rheumatoid arthritis</field>
<field name="value">Transcriptomics</field>
</element>
</element>
</element>
</element>
<element name="bundles">
<element name="bundle">
<field name="name">THUMBNAIL</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">aterido-fii-comb.pdf.jpg</field>
<field name="originalName">aterido-fii-comb.pdf.jpg</field>
<field name="description">IM Thumbnail</field>
<field name="format">image/jpeg</field>
<field name="size">36531</field>
<field name="url">http://repositori.upf.edu/bitstream/10230/43304/3/aterido-fii-comb.pdf.jpg</field>
<field name="checksum">fa68b1e4dda997595cded29c0fdee99e</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">3</field>
</element>
</element>
</element>
<element name="bundle">
<field name="name">TEXT</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">aterido-fii-comb.pdf.txt</field>
<field name="originalName">aterido-fii-comb.pdf.txt</field>
<field name="description">Extracted text</field>
<field name="format">text/plain</field>
<field name="size">75213</field>
<field name="url">http://repositori.upf.edu/bitstream/10230/43304/2/aterido-fii-comb.pdf.txt</field>
<field name="checksum">aa01610babf740550a64154fbb3e1060</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">2</field>
</element>
</element>
</element>
<element name="bundle">
<field name="name">ORIGINAL</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">aterido-fii-comb.pdf</field>
<field name="format">application/pdf</field>
<field name="size">999332</field>
<field name="url">http://repositori.upf.edu/bitstream/10230/43304/1/aterido-fii-comb.pdf</field>
<field name="checksum">f6b7b910b3c9dbaf04fba9d71875bd76</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">1</field>
</element>
</element>
</element>
</element>
<element name="others">
<field name="handle">10230/43304</field>
<field name="identifier">oai:repositori.upf.edu:10230/43304</field>
<field name="lastModifyDate">2021-12-17 12:56:54.413</field>
</element>
<element name="repository">
<field name="name">Repositori digital de la UPF</field>
<field name="mail">repositori@upf.edu</field>
</element>
</metadata>